15.53
-0.27 (-1.71%)
| Previous Close | 15.80 |
| Volume | 1,083,259 |
| Price / Earnings (Forward) | 24.69 |
| Price / Sales | 2.98 |
| Price / Book | 2.39 |
| 52 Weeks Range | |
| TTM Dividend Yield | 0.30% |
| Profit Margin | 11.16% |
| Operating Margin (TTM) | 13.97% |
| Diluted EPS (TTM) | 0.540 |
| Quarterly Revenue Growth (YOY) | 8.70% |
| Quarterly Earnings Growth (YOY) | 40.90% |
| Total Debt/Equity (MRQ) | 27.86% |
| Current Ratio (MRQ) | 1.83 |
| Operating Cash Flow (TTM) | 184.02 M |
| Levered Free Cash Flow (TTM) | -113.47 M |
| Return on Assets (TTM) | 4.88% |
| Return on Equity (TTM) | 9.14% |
News Mood
-
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
10 Nov, 12:47PM
-
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
04 Nov, 4:12AM
-
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
03 Nov, 3:07PM
-
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
04 Nov, 6:15AM
-
Why Stevanato Group Bears Were Right Before The Drop
04 Nov, 4:10PM
AIStockmoo Score
| Value 30% | 0.7 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Cheaper than its usual valuation. info | |
| Low debt. Ample short-term liquidity. Negative cash flow. info | |
| Earns below its cost of capital. Returns on capital falling. info | |
| Timing 30% | -3.5 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. A recent move above resistance has not been confirmed. info | |
| Recent bullish reversal pattern: Bullish engulfing. info | |
| Below its medium-term trend line. info | |
| Sentiment 20% | 0.1 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Smart Money 20% | 2.1 |
| Insiders net buying recently. info | |
| Institutions net +12.52% of shares in their latest 13F filings: 67 holders increased, 69 decreased (quarter to 30 Sep 2026). info | |
| Market and sector conditions are neutral. | |
| Market environment cautious. info | |
| Sector outperforming the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Trend down on all three terms. Short-term momentum falling. info | |
| Price is between support and resistance. info | |
| Final Score | -0.33 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Mixed |
| Medical Instruments & Supplies (Global) | Mixed | Mixed | |
| Stock | Stevanato Group S.p.A. | Mixed | Bullish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| STVN | - | 0.30% | - | 2.39 |
| ALC | - | 0.49% | - | 1.64 |
| RMD | - | 1.08% | - | 5.66 |
| BDX | - | 2.20% | - | 2.41 |
| WST | - | 0.37% | - | 9.67 |
| BLCO | - | - | - | 1.17 |
Select this tab to load the latest available analysis.
|
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Growth |
| % Held by Insiders | 1.68% |
| % Held by Institutions | 112.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nicholas Company, Inc. | 30 Sep 2026 | 743,799 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOREL DONALD E JR | 13.57 | - | 25,000 | 339,250 |
| Aggregate Net Quantity | 25,000 | |||
| Aggregate Net Value ($) | 339,250 | |||
| Aggregate Avg. Buy ($) | 13.57 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOREL DONALD E JR | Director | 06 Nov 2026 | Buy (+) | 25,000 | 13.57 | 339,250 |
Institutions
Institutional ownership: 94.54%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 67 | 8,329,131 |
| Decreased | 69 | 6,219,678 |
| New | 28 | 5,656,951 |
| Sold out | 23 | 1,508,891 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 16 Nov 2026 | Yahoo Finance |
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy, November 16, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in three upcoming… |
| 10 Nov 2026 | Yahoo Finance |
Broader Biologics Growth Strengthens Stevanato’s (STVN) Long-Term Outlook
Cooper Investors, an investment management firm, released its third-quarter 2026 investor letter for “Cooper Investors Global Equities Fund (Unhedged)”. The letter can be downloaded here. The Fund returned 0.50% net of fees in the quarter, driven by Compounding and Real Asset investments, partially… |
| 04 Nov 2026 | Yahoo Finance |
Why Stevanato Group Bears Were Right Before The Drop
Stevanato Group kept reporting healthy headlines, with Q4 and Q1 updates pointing to solid revenue growth, stronger high-value solutions and reaffirmed guidance. Holding Stevanato Group over the past year would have meant a 42.8% loss, including dividends. If you had bought in believing GLP-1… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Faces Legal Investigation Over GLP 1 Disclosure
Stevanato Group (NYSE: STVN) faces a pending legal investigation into its disclosures after revising its GLP-1-related volume outlook. Law firm SueWallSt is examining whether Stevanato Group complied with U.S. securities disclosure rules following guidance on lower GLP-1 volumes. The probe focuses… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Could Be 42% Undervalued Following Q3 Earnings
Stevanato Group (STVN) just posted its third quarter 2026 earnings, reporting sales of €326.1 million and net income of €41.8 million. These results give investors fresh numbers to reassess the stock. Despite the solid Q3 report and the Aptar Pharma collaboration announced in late October… |
| 04 Nov 2026 | Yahoo Finance |
Stevanato Group Q3 Earnings Call Highlights
Stevanato Group (NYSE:STVN) reported third-quarter 2026 revenue growth of 8% to €326.1 million, supported by continued expansion in its biopharmaceutical and diagnostic solutions business despite weaker demand tied to GLP-1 therapies and a decline in its engineering segment. Chairman and Chief Exec… |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group S.p.A. Q3 2026 Earnings Call Summary
Moby summary of Stevanato Group S.p.A.'s Q3 2026 earnings call… |
| 03 Nov 2026 | Yahoo Finance |
Stevanato (STVN) Q3 2026 Earnings Call Transcript
Biologics demand held firm while GLP-1 volumes shape the 2027 outlook. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8% as Non-GLP ...
Stevanato Group SpA (STVN) delivered solid Q3 2026 organic growth and margin expansion while flagging a temporary, single-customer GLP-1 volume decline expected to moderate 2027 growth. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group (STVN) Surpasses Q3 Earnings and Revenue Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +5.88% and +3.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 03 Nov 2026 | Yahoo Finance |
Stevanato: Q3 Earnings Snapshot
PADUA, Italy (AP) — PADUA, Italy (AP) — Stevanato Group SpA (STVN) on Tuesday reported third-quarter earnings of $48.The Padua, Italy-based company said it had profit of 17 cents per share. |
| 03 Nov 2026 | Yahoo Finance |
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
PIOMBINO DESE, Italy, November 03, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of… |
| 28 Oct 2026 | Yahoo Finance |
Stevanato Group S.p.A. (STVN) Rallies on 2Q26 Revenue Growth and EBITDA Margin Expansion
Conestoga Capital Advisors, an asset management company, released its third-quarter 2026 investor letter. The letter can be downloaded here. In 2026, Small Caps initially outperformed but faced challenges in the third quarter, marked by the Russell 2000 Growth Index’s -9.4% decline versus the S&P… |
| 27 Oct 2026 | Yahoo Finance |
Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection
CRYSTAL LAKE, Ill., October 27, 2026--Aptar Pharma and Stevanato Group Collaborate to Help Accelerate Pre-Filled Syringe System Selection… |
| 27 Oct 2026 | Yahoo Finance |
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S.p.A. (NYSE: STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma… |
| 20 Oct 2026 | Yahoo Finance |
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
PIOMBINO DESE, Italy, October 20, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third… |
| 01 Oct 2026 | Yahoo Finance |
Ensera launches alliance network with SHL Medical, Stevanato Group, Ypsomed, Argonaut and American Injectables
Ensera, a global CDMO specializing in commercialization support for injectable drug programs, has launched the Ensera Alliance Network, bringing together leading device platform and fill-finish specialists to address the complexity of commercializing drug-device combination products. |
| 01 Oct 2026 | Yahoo Finance |
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| 18 Sep 2026 | Yahoo Finance |
electroCore (ECOR) Stock Jumps 6.9%: Will It Continue to Soar?
electroCore (ECOR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| Show more | ||
| TTM Dividend Yield | 0.30% |
| 4Y Average Dividend Yield | 0.19% |
| Payout Ratio | 11.52% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 04 Jun 2024 | 10 Apr 2024 | 15 Jul 2024 | 0.0573 Cash |
| 07 Jun 2023 | 05 Apr 2023 | 17 Jul 2023 | 0.0577 Cash |
| 13 Jun 2022 | 11 Apr 2022 | 13 Jul 2022 | 0.0546 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.057 | 1 | 0.26 |
| 2023 | 0.058 | 1 | 0.21 |
| 2022 | 0.055 | 1 | 0.30 |
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |